NI200700316A - Aminopirimidinas como moduladores de la cinasa - Google Patents

Aminopirimidinas como moduladores de la cinasa

Info

Publication number
NI200700316A
NI200700316A NI200700316A NI200700316A NI200700316A NI 200700316 A NI200700316 A NI 200700316A NI 200700316 A NI200700316 A NI 200700316A NI 200700316 A NI200700316 A NI 200700316A NI 200700316 A NI200700316 A NI 200700316A
Authority
NI
Nicaragua
Prior art keywords
compounds
kit
trkb
flt3
cell
Prior art date
Application number
NI200700316A
Other languages
English (en)
Inventor
David Gaul Michael
Xu Guozhang
Andrew Baumann Christian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NI200700316A publication Critical patent/NI200700316A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de aminopirimidinas de Fórmula I: donde R3, B, Z, Q, p, q y R1 son como se definen en el presente documento, el uso de tales compuestos como moduladores de la proteína de tirosina cinasa, en particular inhibidores de FLT3 y/o c-kit y/o TrkB, el uso de tales compuestos para reducir o inhibir la actividad de la cinasa de FLT3 y/o c-kit y/o TrkB en una célula o en un sujeto, y el uso tales compuestos para prevenir o tratar en un sujeto un trastornos prolífero de células y/o trastornos relacionados a FLT3 y/o c-kit y/o TrkB. La presente invención también se refiere a composiciones farmacéuticas que comprenden los compuestos de la presente invención y a métodos para tratar condiciones tales como canceres y otros trastornos prolíferos de células.
NI200700316A 2005-06-10 2006-06-07 Aminopirimidinas como moduladores de la cinasa NI200700316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971705P 2005-06-10 2005-06-10
US75108405P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
NI200700316A true NI200700316A (es) 2009-03-03

Family

ID=36929309

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700316A NI200700316A (es) 2005-06-10 2006-06-07 Aminopirimidinas como moduladores de la cinasa

Country Status (17)

Country Link
US (1) US20060281764A1 (es)
EP (1) EP1896029A1 (es)
JP (1) JP2008543760A (es)
KR (1) KR20080028911A (es)
AR (1) AR053895A1 (es)
AU (1) AU2006258054A1 (es)
BR (1) BRPI0611963A2 (es)
CA (1) CA2611470A1 (es)
EA (1) EA200800015A1 (es)
EC (1) ECSP077991A (es)
GT (1) GT200600248A (es)
IL (1) IL187693A0 (es)
NI (1) NI200700316A (es)
NO (1) NO20080163L (es)
PE (1) PE20070076A1 (es)
TW (1) TW200718693A (es)
WO (1) WO2006135644A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615880A2 (pt) * 2005-09-13 2011-05-31 Palau Pharma Sa compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica
KR101177729B1 (ko) 2006-09-08 2012-09-07 에프. 호프만-라 로슈 아게 벤조트리아졸 키나아제 조절제
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
CA2680398A1 (en) * 2007-03-20 2008-09-25 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
US20110275094A1 (en) * 2008-11-06 2011-11-10 Gunawardane Ruwanthi N Phosphorylated fms-related tyrosine kinase 3 biomarker assay
CN102272120B (zh) * 2008-11-07 2013-12-25 H.隆德贝克有限公司 生物活性酰胺
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
JP6959332B2 (ja) * 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
EA201992083A1 (ru) 2017-03-16 2020-03-18 Кринетикс Фармасьютикалс, Инк. Модуляторы соматостатина и их применения
WO2019157458A1 (en) * 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2020061046A1 (en) 2018-09-18 2020-03-26 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
IL305011A (en) 2021-02-17 2023-10-01 Crinetics Pharmaceuticals Inc Crystal forms of a somatostatin modulator

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523942A (ja) * 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors

Also Published As

Publication number Publication date
JP2008543760A (ja) 2008-12-04
NO20080163L (no) 2008-03-07
EP1896029A1 (en) 2008-03-12
AR053895A1 (es) 2007-05-23
GT200600248A (es) 2007-03-14
WO2006135644A1 (en) 2006-12-21
AU2006258054A1 (en) 2006-12-21
TW200718693A (en) 2007-05-16
PE20070076A1 (es) 2007-02-09
BRPI0611963A2 (pt) 2010-10-13
ECSP077991A (es) 2008-01-23
EA200800015A1 (ru) 2008-06-30
IL187693A0 (en) 2008-08-07
CA2611470A1 (en) 2006-12-21
US20060281764A1 (en) 2006-12-14
KR20080028911A (ko) 2008-04-02

Similar Documents

Publication Publication Date Title
NI200700313A (es) Aminopirimidinas como moduladores de la cinasa .
NI200700316A (es) Aminopirimidinas como moduladores de la cinasa
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
CR9652A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
NI200700311A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3
NI200800179A (es) Triazolopiridazinas como moduladores de la tirosina cinasa
ECSP109953A (es) Derivados de piridazinona
UY29246A1 (es) Nuevos compuestos
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
ECSP10010361A (es) Derivados de piridazinona
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
CL2012003637A1 (es) Compuestos derivados de quinazolina o triazolopiridina sustituidos, inhibidores selectivos de tirosina quinasa; medicamento; composicion farmaceutica; y su uso para tratar, prevenir o mejorar edema retiniano/macular, degeneración macular relacionada con la edad y derrame vascular retiniano relacionado con isquemia, entre otras.
EA200702136A1 (ru) Композиции станнсопорфина и их применение
NI200700312A (es) Intermediarios útiles en las síntesis de moduladores de la cinasa de alquilquinoleína y alquilquinazolina y métodos de síntesis relacionados.
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa